1Kessler RC, McGonogle DK, Zhao S, et al. Lifetime and 12-month prevalence of DSM-Ⅲ-R pschiatric disorders in the United States. Results from the National Comorbity Survey. Arch Gen Psychiatry,1994, 5: 8～19
2Davidson JRT, Potts N, Richichi E. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol, 1993, 13:423～28
3Gelernter CS, Uhde TW, Cimbolic P. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry, 1991, 48: 938～945
4Jitender Sareen, Murray Stein. A review of the epidemiology and approaches to the treatment of social anxiety disorder. Drugs, 2000, 59(3): 497～509
5Simpson BH, Schneier FR, Campeas RB. Imipramine in the treatment of social phobia. J Clin Psychopharmacol, 1998, 18(2): 135 ～5
6Jonathan RT Davidson. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry, 1998, 59 (suppl 17): 47～51
7Viet IM van, Boer JA den. Psychopharmacological treatment of social phobia., a double-blind placebo-controlled study with fluvoxemine. Psychopharmacology, 1994, 115: 128～134
8Stein MB, Fyer AJ. Fluvoxemine treatment of social phobia: a double-blind placebo-controlled study. American Journal of Psychiatry,1999, 156(5): 756～60
9Stein MB, Liebowitz MR. Paroxetine treatment of generalized social phobia: a randomized controlled trial. JAMAm 1998, 280:708～713
10Baldwin D, Bobes J, Stein DJ. A randomised double-blind placebocontrolled study of paroxetine in the treatment of social phobia.British Journal of Psychiatry, 1999, 175: 120～6
